Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Operations (2023 - 2025)

CG Oncology's Cash from Operations history spans 3 years, with the latest figure at 36170000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 75.06% year-over-year to 36170000.0; the TTM value through Dec 2025 reached 132300000.0, down 68.08%, while the annual FY2025 figure was 132300000.0, 68.08% down from the prior year.
  • Cash from Operations reached 36170000.0 in Q4 2025 per CGON's latest filing, up from 38930000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 7986000.0 in Q1 2023 to a low of 38930000.0 in Q3 2025.
  • Average Cash from Operations over 3 years is 21391000.0, with a median of 18391000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: crashed 225.72% in 2024, then decreased 12.55% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 14645000.0 in 2023, then tumbled by 41.09% to 20662000.0 in 2024, then plummeted by 75.06% to 36170000.0 in 2025.
  • Per Business Quant, the three most recent readings for CGON's Cash from Operations are 36170000.0 (Q4 2025), 38930000.0 (Q3 2025), and 27923000.0 (Q2 2025).